Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +75

Moderna (MRNA) Soars to Fresh High Ahead of Pipeline Updates This Week

Clinical trial results Drug approval AI-generated analysis

πŸ“ˆ Moderna stock jumped to a fresh three-year high of $176.86 ahead of critical pipeline updates regarding its melanoma treatment.

πŸ”¬ The Phase 3 INTerparth-001 trial for intismeran autogene combined with Merck's Keytruda achieved primary and secondary endpoints for recurrence-free survival.

πŸ† This readout represents the first positive Phase 3 data for a combination of individualized neoantigen therapy and mRNA-based cancer therapy.

πŸ“Š Institutional conviction strengthened in Q2 as hedge fund holdings increased by 10% to $1.5 billion quarter-on-quarter.

πŸ—“οΈ Moderna is scheduled to present further data at the Bernstein Insights Healthcare Forum on September 23, 2026.

🌍 The same trial results will be presented at the ESMO Congress 2026 in Madrid from October 23 to 27, 2026.

🎯 The therapy targets melanoma, a disease expected to cause 8,500 deaths in the US alone by the end of 2026.

πŸ’° Moderna and Merck partnered to develop this combination therapy for the most common type of skin cancer.

πŸ“‰ Despite some hedge funds exiting positions, existing investors are increasing exposure amid optimism for long-term growth.

πŸš€ The trial demonstrated a clinically meaningful improvement over Keytruda alone in treating melanoma patients.

Bullish Signals
  • Moderna stock reached a new three-year high of $176.86, signaling strong investor confidence ahead of major clinical data releases.
  • The Phase 3 INTerparth-001 trial achieved its primary endpoint of recurrence-free survival and key secondary target of distant metastasis-free survival for melanoma treatment.
  • This readout marks the first positive Phase 3 result for a combination of individualized neoantigen therapy and mRNA-based cancer therapy, demonstrating superiority over Keytruda alone.
  • Institutional conviction strengthened in Q2 with combined hedge fund holdings increasing by 10% to $1.5 billion despite a slight drop in the number of funds holding positions.
  • The potential approval of intismeran autogene addresses a massive market opportunity, targeting an estimated 112,000 new US melanoma cases annually.
Full Analysis
Moderna Inc. (NASDAQ:MRNA) shares surged to a new three-year high of $176.86, driven by investor anticipation of upcoming clinical trial data for its melanoma treatment candidate, intismeran autogene. The stock traded above $174 as the market reacted positively to the prospect of significant pipeline updates at two major health conferences scheduled for late September and early October 2026. The company is set to present Phase 3 trial results from the INTerparth-001 study at the Bernstein Insights Healthcare Forum on Wednesday, September 23, and again at the European Society for Medical Oncology (ESMO) Congress in Madrid. These trials evaluate the combination of intismeran autogene with Merck's Keytruda for treating melanoma. Moderna announced that the Phase 3 trial achieved its primary endpoint of recurrence-free survival and the key secondary target of distant metastasis-free survival. This readout marks a historic milestone as the first positive Phase 3 data for a combination of individualized neoantigen therapy and mRNA-based cancer therapy, demonstrating clinically meaningful improvement over Keytruda alone. The potential approval of this therapy addresses a massive market need, with the US expected to see 112,000 new melanoma cases by year-end. Institutional investors are strengthening their conviction in Moderna, evidenced by a 10% quarter-on-quarter increase in combined hedge fund holdings to $1.5 billion, despite a slight reduction in the number of funds holding positions.